Document:

exv10w4

Exhibit 10.4

AMENDMENT NO. 1 TO

ADVISORY AGREEMENT

     This
AMENDMENT NO. 1 TO ADVISORY AGREEMENT (this “Amendment”) is
made this 21st day
of January, 2009, by and among Shopoff Properties Trust, Inc., a Maryland corporation (the
“Company”), Shopoff Partners, L.P., a Delaware limited partnership (the “Operating Partnership”),
and Shopoff Advisors, L.P., a Delaware limited partnership (the “Advisor”).

RECITALS:

     WHEREAS, the Company, the Operating Partnership, and the Advisor are parties to that certain
Advisory Agreement, dated as of August 29, 2007 (the “Advisory Agreement”), pursuant to which the
Advisor provides advice and assistance to the Company and the Operating Partnership in the
operation of the Company as a real estate investment trust;

     WHEREAS, it is the intent parties that the Company reimburse the Advisor for reasonable
Acquisition Expenses incurred in connection with the sourcing, selection, evaluation and
acquisition of, and investment in Real Estate Assets or Real Estate Related Investments, whether or
not such properties are acquired or investments are made;

     WHEREAS, the Advisory Agreement contains a limitation on the maximum percentage of the
contract price constituting Acquisition Expenses that may be reimbursed to the Advisor and the
parties believe that it is in the best interests of the Company to permit the Advisor to incur the
reasonable expenses necessary to conduct adequate due diligence of all properties considered for
acquisition;

     WHEREAS, the parties believe it is in the best interests of the Company to amend the Advisory
Agreement to delete Section 10(a)(ii), which provides for the limitation on Acquisition Expenses,
and to correct a clerical error in the Advisory Agreement;

     WHEREAS, capitalized terms not otherwise defined herein shall have the meaning given to them
in the Advisory Agreement.

     NOW, THEREFORE, in consideration of the premises, covenants and agreements contained herein,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows.

     1.      Amendment.

     1.1      Section 10(a)(ii) of the Advisory Agreement is hereby deleted in its entirety and replaced
with the following:

     “(ii) subject to Section 10(a)(xvi), all reasonable Acquisition Expenses incurred in
connection with the investigation, selection and acquisition of a Real Estate Asset or a Real
Estate Related Investment;”

     1.2      As a typographical correction, the following text is hereby removed as the last clause of
Section 10(a)(ii) and is hereby added as Section 10(a)(xvii) of the Advisory Agreement:

     “(xvii) the actual out-of-pocket cost of goods and services used by the Company and obtained
from entities not affiliated with the Advisor including brokerage and other fees paid in connection
with the purchase, operation and sale of Real Estate Assets.”

     2.      Effect of Amendment. Except as expressly amended by this Amendment, the terms of
the Advisory Agreement remain in full force and effect. In the event of any conflict or
inconsistency between the provisions of the Advisory Agreement and the provisions of this
Amendment, the provisions of this Amendment shall control.

 

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above.

	 	 	 	 	 
	 	SHOPOFF PROPERTIES TRUST, INC.

 	 
	 	By:  	/s/ William A. Shopoff
 	 
	 	 	Name:  	William A. Shopoff 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 

	 	 	 	 	 
	 	SHOPOFF ADVISORS, L.P.

 	 
	 	By:  	/s/ William A. Shopoff
 	 
	 	 	Name:  	William A. Shopoff 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 

	 	 	 	 	 
	 	SHOPOFF PARTNERS, L.P.

 	 
	 	By:  	/s/ William A. Shopoff
 	 
	 	 	Name:  	William A. Shopoff 	 
	 	 	Title:  	President and Chief Executive Officerexv10w13

Exhibit
10.13

First American Title Company

5 First American Way, Santa Ana, CA 92707

Phone - (714)250-5381 Fax - (714)913-6372

AMENDED/SUPPLEMENTAL ESCROW INSTRUCTIONS

			
	 	 	 
	

	To: First American Title Company
	 	January 13, 2009
	

	 
	 	File No:   OSA-3152741 (jg)
	 	 	 
	

	Re: APN 349-240-043-90, Lake Elsinore, CA	 	 
	

The above referenced escrow is hereby modified in the following particulars only:

Close
of Escrow: The Close of Escrow is hereby amended to be on or
before: January 30, 2009.

ALL OTHER TERMS AND CONDITIONS OF THIS ESCROW WILL REMAIN THE SAME.

	 	 	 	 	 
	TSG Little Valley, L.P., a California
limited partnership	 	 
	 
	 	 	 	 

	By:

	 	Portfolio Partners, Inc., a California	 	 
	 

	 	corporation, its General Partner	 	 
	 
	 	 	 	 
	

By::

	 	/s/ Stevan J. Gromet
 
STEVAN J. GROMET

Its: President
	 	 

Page 1 of 2

 

			
	 	 	 
	First American Title Company
	 	File No.:OSA-3152741 (jg )

	 	 	 	 	 
	Shopoff Advisors, L.P., a Delaware
limited partnership	 	 
	 
	 	 	 	 
	By:

	 	The Shopoff Corporation, a Delaware	 	 
	 

	 	corporation, its General Partner	 	 
	 
	 	 	 	 
	

By:: 
	 	/s/ William A. Shopoff
 
William A. Shopoff

Its: President and CEO
	, 	 

Page 2 of 2exv10w17

EXHIBIT 10.17

CONFIDENTIAL

EXECUTION VERSION

PATENT LICENSE AGREEMENT

     This Patent License Agreement, dated as of March 30, 2007 (the “Patent License Agreement”), is
by and among Purdue Pharma L.P., a Delaware limited partnership, The P.F. Laboratories, Inc., a New
Jersey corporation, Purdue Pharmaceuticals L.P., a Delaware limited partnership (the foregoing are
individually and collectively referred to as the “Purdue Companies”), and IMPAX Laboratories, Inc.,
a Delaware corporation (“IMPAX”). The Purdue Companies and IMPAX are sometimes referred to herein
individually as a “Party” and collectively as the “Parties”.

WITNESSETH:

     WHEREAS, the Purdue Companies are the owners of United States patent numbers 5,549,912,
5,508,042 and 5,656,295 (the “Purdue Patents”), relating to and protecting controlled-release
oxycodone products, including the product OxyContin®, a controlled-release oxycodone
product; and

     WHEREAS, certain of the Purdue Companies and IMPAX (i) are involved in litigation, Civil
Actions Nos. 02 CV 2803, 02 CV 7569, 02 CV 8036 (SHS) (SDNY), and (ii) were involved in Civil
Action NO. 02-1481 (JJF) (D.Del.), which action was dismissed without prejudice (the actions
referred to the clauses (i) and (ii) above are collectively referred to herein

 

 

as, the “Actions”), concerning, inter alia, the validity and enforceability of the Purdue
Patents, as well as the infringement by IMPAX of the Purdue Patents resulting from IMPAX’s
requesting approval from the United States Food and Drug Administration (the “FDA”) of generic
versions of OxyContin® products through their submission of ANDA No. 76-318 and ANDA No.
76-446, along with all amendments and supplements thereto (collectively referred to herein as the
“IMPAX ANDA”), and IMPAX’s subsequent manufacture, use, sale, offer to sell or importation of
oxycodone pursuant to the IMPAX ANDA; and

     WHEREAS, the Purdue Companies and IMPAX have entered into a settlement agreement, dated as of
the date hereof (the “Settlement Agreement”), to resolve the Actions and as a result of and
pursuant to the Settlement Agreement, the Purdue Companies desire to grant to IMPAX certain limited
license rights under the Purdue Patents to manufacture, use, offer to sell, sell and have sold
generic versions of OxyContin® products described in IMPAX ANDA in the United States.

     NOW THEREFORE, the Parties agree as follows:

     1. License Grant; Option.

          (a) Grant of License. The Purdue Companies hereby grant to IMPAX a non-exclusive,
royalty-free, non-transferable (except as provided in Sections 1(d) and 12 below) license of
limited duration under the Purdue Patents to make, have made, use, offer to Sell (as defined
below), Sell and have Sold not more than that number of bottles each containing 100 tablets
(“Bottles”) equal to the difference between (i) 523,000 minus (ii) the number of Bottles Sold by
IMPAX, DAVA Pharmaceuticals, Inc. (“DAVA”) or any party acting on their behalf from March 1, 2007
until and including the day which immediately precedes the date the License period described below
commences (the “License Amount”), allocated among dosage strengths

2

 

as set forth in Section 1(b) below, of the generic versions of OxyContin® products
specifically described in, and sold under, the IMPAX ANDA as approved as of the Signing Date (the
“IMPAX Product”) in the United States (the “License”), during the period commencing at 12:01 a.m.,
New York City time, on the Signing Date and terminating upon the earlier of (the “License
Termination Date”): (i) 11:59 p.m., New York City time on June 14, 2007; and (ii) the date upon
which this Patent License Agreement is terminated in accordance with Section 10 hereof. For
purposes of Sections 1(a), 1(b) and 1(d) hereof, the terms “Sell, “Selling”, or “Sold” mean selling
and shipping by IMPAX, DAVA, or any party acting on their respective behalves to a third party bona
fide purchaser for commercial sale. For the avoidance of any doubt, sales and shipments of Bottles
by IMPAX to DAVA for subsequent selling and shipping to a third party bona fide purchaser for
commercial sale under a sublicense validly granted by IMPAX to DAVA under Section 1(d) shall be
permitted under the terms and conditions of this Patent License Agreement until the License
Termination Date and shall be excluded for purposes of determining the Bottles Sold hereunder.

          (b) The Bottles Sold by IMPAX, DAVA or any party acting on their respective behalves, from
March 1, 2007 through the License Termination Date shall be allocated according to dosage strength
such that the quantity of Bottles Sold of each dosage strength shall
not vary by more than twelve and one half percent (12.5%) from the number of Bottles set forth next to each dosage strength in
Schedule 1 hereto; provided, that such variations, in the aggregate, may not increase the License
Amount or increase the aggregate number of labeled kilograms of oxycodone hydrochloride in the
Bottles Sold pursuant to this License above 349 kilograms per 100,000 Bottles Sold.

3

 

          (c) Immediately upon the occurrence of the License Termination Date, all solicitations for
sale of IMPAX Product, offers to sell IMPAX Product, sales of IMPAX Product and shipments IMPAX
Product into interstate commerce for commercial sale in the United States under the License shall
cease as set forth in Section 2 hereof. During the period of the License, IMPAX shall use its
commercially reasonable efforts to sell the License Amount. Nothing herein will prohibit IMPAX
from making, having made, using, selling, or offering for sale, any IMPAX Product, after the
Terminal Date and subject to the provisions of the Settlement Documents.

          (d) IMPAX shall have no right to sublicense the license rights granted herein except to grant
only the limited, non-transferable right to Sell, offer to Sell and distribute IMPAX Product
permitted to be Sold hereunder to DAVA under the terms and conditions of this Patent License
Agreement. Except as expressly granted herein, no other right, written or oral license or
sublicense, covenant not to sue, waiver or release of future infringement of other written or oral
authorization is granted or implied by this Patent License Agreement. The Purdue Companies reserve
all rights not expressly granted herein, including the right to sue for patent infringement for
sales that are not permitted pursuant to the License or the Supplemental License (as defined in the
Supplemental License Agreement), except to the extent such suit is prohibited by Section 8(b)
hereof. For the avoidance of any doubt, nothing herein shall preclude the Purdue Companies, for
themselves or through a third party acting on their behalf, from soliciting offers for sale,
offering for sale, selling, shipping or causing to be shipped a generic version of
OxyContin® produced under NDA No. 20-553 (“Generic NDA Equivalent”).

          (e) Supplemental License Agreement. Subject to compliance by IMPAX and, subject to
Section 11, all entities acting on IMPAX’s behalf with the terms of this Patent License

4

 

Agreement and, in the case of IMPAX, the Settlement Agreement, including, without limitation,
the provisions of Section 2 hereof, IMPAX and the Purdue Companies shall enter into a Supplemental
License Agreement in the form of Exhibit A hereto (the “Supplemental License Agreement”). Such
Supplemental License Agreement shall be executed by the Parties on, and shall become effective as
of, November 27, 2007; provided, however, that the Purdue Companies shall have the right to
designate an earlier execution and effective date with IMPAX’s written consent.

     2. Effective Date and Termination Date. (a) The provisions of Sections 1, 2, 3(a),
and 4 through 20 of this Patent License Agreement shall become effective on the Signing Date. All
other provisions of this Patent License Agreement shall become effective on the Effective Date, as
defined in the Settlement Agreement. The Patent License Agreement and all rights granted to IMPAX
under the License (including any permitted sublicense thereof) will terminate on the License
Termination Date; provided, however, that nothing herein shall limit any rights granted to IMPAX
pursuant to an effective Supplemental License Agreement. Without limiting the foregoing, from and
after the License Termination Date until the Terminal Date, except as otherwise expressly provided
in the Supplemental License Agreement, IMPAX may not solicit offers for, offer to sell, sell, ship,
or cause to be shipped or distributed, or indemnify others regarding or participate in the profits
of others arising from the sale of any controlled-release oxycodone product that (i) is covered by
the IMPAX ANDA or (ii) otherwise infringes any of the claims of any of the Purdue Patents,
including without limitation any sales or shipments from IMPAX of IMPAX Product into interstate
commerce for commercial sale in the United States, including without limitation any sales or
shipments from IMPAX to DAVA; provided, however, that this sentence shall not be deemed to be
breached in connection with any IMPAX Product

5

 

that is shipped to a bona fide purchaser for commercial sale by IMPAX or DAVA, as permitted
under this Patent License Agreement, prior to the License Termination Date. Except as otherwise
provided in the Supplemental License Agreement, from and after the License Termination Date until
the Terminal Date, IMPAX shall prohibit DAVA or any licensee, distributor, or any other party
acting in a similar capacity to DAVA, from soliciting offers for, offering to sell, selling,
shipping, or causing to be shipped, IMPAX Product into interstate commerce for commercial sale in
the United States; provided, however, that this sentence shall not be deemed to be breached in
connection with any IMPAX Product that is shipped by DAVA to a bona fide third party purchaser for
commercial sale, as permitted under this Patent License Agreement, prior to the License Termination
Date. Promptly after the License Termination Date, IMPAX shall segregate the IMPAX Product and
conspicuously place a sign where it can easily be seen at the location in IMPAX’s facility where
the IMPAX Product is separately held, identifying the IMPAX Product as not available for sale or
distribution. Following the License Termination Date, IMPAX shall deliver to the Purdue Companies
certificates from the Chief Financial Officer of IMPAX or any other executive officer of IMPAX
certifying (i) that IMPAX ceased soliciting offers for, offering to sell, selling, shipping or
causing to be shipped or distributed, or indemnifying others regarding or participating in the
profits of others arising from the sale of any controlled-release oxycodone product specified in
clause (i) and (ii) herein (and has instructed DAVA to cease soliciting offers for, offering to
sell, selling, shipping or causing to be shipped or distributed), IMPAX Product into interstate
commerce for commercial sale in the United States on or before the License Termination Date, (ii)
the number of Bottles of IMPAX Product in each dosage strength sold by IMPAX from March 1, 2007 to
the License Termination Date, (iii) that no sales resulting in sales above the Licensed Amount were
made by IMPAX

6

 

prior to the License Termination Date, (iv) that all inventories of IMPAX Product in IMPAX’s
possession or control and remaining on the License Termination Date have been quarantined and (v)
that it has requested a certificate from DAVA and any party acting on IMPAX’s or DAVA’s behalf
making the certifications referred to in clauses (ii) through (v) above with respect to DAVA or
such party. The certifications referred to in clause (i) above shall be delivered two (2) business
days following the License Termination Date and the certifications referred to in clauses (ii)-(v)
above shall be delivered within ten (10) calendar days following the License Termination Date. The
certifications of DAVA and any other party acting on IMPAX’s or DAVA’s behalf shall be delivered as
soon as possible following the License Termination Date.

          (b) IMPAX acknowledges and agrees that IMPAX’s violation or breach of this Patent License
Agreement would cause the Purdue Companies to suffer substantial damages and irreparable harm that
could not adequately be remedied by an action at law. Accordingly, IMPAX agrees that Purdue
Companies will be entitled, without limitation, to specific performance or preliminary or permanent
injunctive relief without the requirement of posting a bond in any action, hearing, litigation or
suit for violation or breach of this Patent License Agreement, such rights and remedies being in
addition to all other rights and remedies available to the Purdue Companies request for any
equitable relief that the Purdue Companies have an adequate remedy at law. IMPAX hereby waives and
agrees not to raise or assert as a defense or counterclaim in any action brought by the Purdue
Companies to enforce IMPAX’s obligations hereunder, any contention of non-infringement, invalidity
or unenforceability of the Purdue Patents, or invalidity or unenforceability of the 331 Patent, or
any contention under Federal or
state antitrust or unfair competition laws; provided, however, that IMPAX shall not be
prohibited from providing evidence that the Circuit Court of any U.S. district court has entered a judgment with respect to the validity
and/or enforceability of the Purdue Patents for purposes of determining whether or not the Terminal
Date shall have occurred. In addition to the foregoing rights and
reservations,

7

 

should IMPAX or DAVA (or any other party acting on their respective behalves) ship any IMPAX
Product into interstate commerce for commercial sale in the United States in excess of the Licensed
Amount or after the License Termination Date but prior to the Terminal Date (in either case,
“Excess Sales”), the Purdue Companies shall have the right to receive, and IMPAX agrees to promptly
pay the Purdue Companies (without any waiver or offset by the Purdue Companies of any right to
further damages), an amount equal to $0.12 for each milligram of
oxycodone of Excess Sales sold; provided, however, that the rate per
milligram payable by IMPAX shall be increased by a percentage equal to the amount of any announced percentage
increase in the price of the wholesale acquisition cost of the
Branded Product (as defined in the Supplemental License Agreement) by the Purdue Companies subsequent to the Signing Date. If, and
only if, IMPAX has not complied with Section 11( which shall not, for the avoidance of doubt,
affect the liability of IMPAX to make payments to the Purdue Companies in respect of Excess Sales
under this Section 2(b)), any breach of the provisions of this Section 2 by DAVA or any licensee,
distributor, or nay other party acting in a similar capacity to DAVA shall be deemed to be a breach
by IMPAX of this Patent License Agreement.

          (c) If any of the certificates of the Chief Financial Officer of IMPAX (or any other executive
officer of IMPAX, if applicable) referred to in Section 2(a) hereof is not delivered to the Purdue
Companies in a timely manner, the Purdue Companies shall have, as their sole remedy for such
failure to deliver in a timely manner (as opposed to any noncompliance with any of the other
requirements of this Patent License Agreement) the right to engage KPMG (provided such firm is not
regularly engaged by IMPAX) or other independent certified public accounting firm chosen by the
Purdue Companies and reasonably acceptable to IMPAX (a “CPA Firm”) to conduct an audit of IMPAX for
the purposes of confirming that no

8

 

sales of IMPAX Product resulted in Excess Sales. The CPA firm shall be given access to and
shall be permitted to examine and copy such books and records of IMPAX, and to the extent permitted
by DAVA, of DAVA, as it shall request upon seven (7) business days’ notice having been given by the
Purdue Companies and at all reasonable times on business days for the purpose of reporting to the
Parties that no sales of IMPAX Product resulted in Excess Sales. Prior to any such examination
taking place, the CPA firm shall commit to IMPAX and, to the extent the CPA Firm is afforded access
to DAVA’s books and records, DAVA, to keeping all information and data contained in such books and
records, strictly confidential and shall not disclose such information or copies of such books and
records to any third person, including the Purdue Companies, but shall use the same only for the
purpose of the reviews and/or calculations which the CPA Firm needs to perform in order to confirm
that no sales of IMPAX Product resulted in Excess Sales. Notwithstanding the foregoing, if the CPA
firm determines that sales of IMPAX Product resulted in Excess Sales, then the Purdue Companies
shall be entitled to receive a full written report of the CPA Firm with respect to its findings.
The determination by the CPA Firm following such audit shall be final and binding on the Parties;
provided, however, that IMPAX shall have the right, prior to such determination becoming binding on
the Parties, to make a presentation to the CPA Firm (which presentation shall be completed in one
(1) business day) to ensure such CPA Firm has adequate information to make its determination;
provided further that, the Purdue Companies may be present at such presentation and may make a
presentation to the CPA firm following the IMPAX presentation. If the report of the CPA Firm shows
that sales of IMPAX Product resulted in Excess Sales, IMPAX shall pay to the Purdue Companies (i)
the amount specified in Section 2(b) and (ii) the fees and expenses of the CPA Firm. If the CPA
Firm reports that no such sales resulted in Excess Sales, the Purdue Companies

9

 

shall pay the fees and expenses of the CPA Firm. IMPAX shall cooperate with and shall use its
best efforts to cause DAVA and its Affiliates to cooperate with the CPA firm in conducting such
audit, including, without limitation, by providing sales records relating to their sale of IMPAX
Product.

          (d) The Purdue Companies will use their commercially reasonable efforts to assist IMPAX with
respect to its submission of applications to the Drug Enforcement Administration for quota
allocations of oxycodone hydrochloride for use in manufacturing the IMPAX Product under the License
or the Supplemental License, including providing information about the Settlement Agreement, this
Patent License Agreement and the Supplemental License Agreement relevant to such applications by
IMPAX.

     3. Food and Drug Administration. (a) Pursuant to 21 C.F.R. § 314.94(a)(12)(v), and
within 10 business days after the Signing Date, IMPAX shall submit to the FDA, with a copy to the
Purdue Companies, a statement that IMPAX has been granted a license with respect to the Purdue
Patents with respect to the IMPAX Product, pursuant to the terms of this Patent License Agreement.

          (b) Pursuant to 21 C.F.R. § 314.107(e), within 10 business days of entry of the Consent
Judgment, IMPAX shall submit to the FDA, with a copy to the Purdue Companies, a copy of such
Consent Judgment.

          (c) Pursuant to 21 C.F.R. § 314.94(a)(12)(viii)(A), and upon the earliest to occur of (i) the
Supplemental License Termination Date (as defined in the Supplemental License Agreement), (ii) the
date that is five business days following any termination of this Patent License Agreement by the
Purdue Companies for a material breach by IMPAX under Section 10 of this Patent License Agreement,
and (iii) November 30, 2007, if the Supplemental License

10

 

Agreement has not been entered into, other than as a result of the breach by the Purdue
Companies of their obligations under Section 1.1(e) hereof, IMPAX shall submit to the FDA, with a
copy to the Purdue Companies, an amendment to IMPAX’s certifications in the IMPAX ANDA with respect
to the Purdue Patents, changing those certifications to certifications under 21 C.F.R. §
314.94(a)(12)(i)(A)(3) and requesting that the FDA promptly change the IMPAX ANDA approval from an
effective approval to a tentative approval. In the event the Terminal Date (as defined in the
Settlement Agreement) has occurred prior to the date upon which IMPAX would otherwise be required
to amend, pursuant to the terms of this Section 3(c), IMPAX’s certifications in the IMPAX ANDA,
then IMPAX shall not be required to amend such certifications with respect to the IMPAX Product.
From and after the Terminal Date, nothing herein will prohibit IMPAX from filing or maintaining
with respect to the IMPAX Product a certification, including but not limited to a certification
based on invalidity or unenforceability, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) and 21
C.F.R. § 314.94(a)(12)(i)(A)(4); provided, however, if there is
a vacatur, reversal or settlement of the type referred to in
paragraph 19(x) or (y) of the Settlement Agreement, then within ten
(10) days of the issuance of such reversal or vacatur or within ten
(10) days after being notified in writing by the Purdue Companies of
such settlement, IMPAX shall submit to the FDA, with a
copy to the Purdue Companies, an amendment to IMPAX’s
certifications and requests to the FDA specified in the first sentence
of this Section 3(c).

     4. Registration. IMPAX will be responsible for, and will bear all costs involved in
respect of, the registration of the IMPAX Product with any governmental regulatory agencies.

     5. WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS PATENT LICENSE
AGREEMENT OR IN THE SETTLEMENT AGREEMENT, NEITHER PARTY NOR THEIR AFFILIATES MAKES ANY
REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY
EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY,

11

 

FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, INCLUDING WITHOUT LIMITATION (1) FOR
THE PURDUE COMPANIES, WITH RESPECT TO THE PURDUE PATENTS OR ANY LICENSE GRANTED BY ANY OF THE
PURDUE COMPANIES HEREUNDER, OR (2) ANY MATERIALS OR INFORMATION PROVIDED BY SUCH PARTY OR ANY OF
ITS AFFILIATES UNDER THIS PATENT LICENSE AGREEMENT OR THE SETTLEMENT AGREEMENT, OR (3) WITH RESPECT
TO ANY PRODUCTS OR SERVICES OF EITHER PARTY HERETO OR THEIR AFFILIATES. FURTHERMORE, UNLESS
EXPRESSLY STATED IN THIS PATENT LICENSE AGREEMENT OR IN THE SETTLEMENT AGREEMENT, NOTHING IN THIS
PATENT LICENSE AGREEMENT OR THE SETTLEMENT AGREEMENT SHALL BE CONSTRUED AS A WARRANTY THAT ANY
PATENT, THE PRACTICE OF ANY INVENTION CLAIMED IN AN PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN
THE PURDUE PATENTS OR ANY LICENSE GRANTED BY ANY OF THE PURDUE COMPANIES DO NOT, OR THE MAKING,
HAVE MADE, USING, SELLING, OFFERING FOR SALE OR IMPORTING OF IMPAX PRODUCTS BY IMPAX DOES NOT,
INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY WHO IS NOT AN
AFFILIATE OF THE PURDUE COMPANIES. IT IS HEREBY AGREED AND ACKNOWLEDGED BY IMPAX THAT THE PURDUE
COMPANIES ARE GIVING NO GUARANTEE OR WARRANTY, EXPRESS OR IMPLIED, TO IMPAX IN RELATION TO THE
SAFETY OR THERAPEUTIC EFFECTIVENESS OF THE IMPAX PRODUCT. FURTHER, IMPAX WILL NOT GIVE ANY SUCH
GUARANTEE OR WARRANTY TO ANY THIRD PARTIES ON BEHALF OF THE PURDUE COMPANIES.

12

 

     6. Bankruptcy. The License is, and shall otherwise be deemed to be, for purposes of
Section 365(n) of Title XI of the United States Code (the “Bankruptcy Code”), a license of rights
to “intellectual property,” as defined in Section 101(56) of the Bankruptcy Code.

     7. Indemnification. (a) IMPAX shall defend, indemnify and hold harmless the Purdue
Companies, their Affiliates and the respective owners, directors, officers, agents and employees of
each of them (collectively, the “Purdue Parties”), from and against any and all expenses, demands,
liabilities, damages or money judgments (“Losses”) incurred by or rendered against the Purdue
Parties resulting from (i) any claim, action or proceeding by any third party arising out of the
making, use, offer for sale or sale of the IMPAX Product or any products previously made, used or
sold under the IMPAX ANDA, (ii) any claim, action or proceeding by any third party arising out of
any material breach by IMPAX of any of its representations, warranties, covenants or agreements
made under this Patent License Agreement, and (iii) any breach by IMPAX of the fourth through the
sixth sentences of Section 2(a) of this Patent License Agreement; provided, however, that IMPAX
will not be liable to indemnify the Purdue Parties for any Losses of the Purdue Parties to the
extent such Losses were caused by: (x) the negligence or willful misconduct or wrongdoing of the
Purdue Parties or (y) any material breach by the Purdue Parties of their representations,
warranties, covenants or agreements under this Patent License Agreement and, provided, further,
that IMPAX’s maximum liability for claims made (other than claims based on willful misconduct) by
the Purdue Companies under Section 7(a)(ii) with respect to
claims made by Teva or Endo and for claims made
(other than claims based on willful misconduct) by the Purdue Companies under Section 7(a)(iii),
shall be limited to the greater of (A) IMPAX’s aggregate
gross margin from the sale of IMPAX Product after the Signing Date
and (B) $0.06 per milligram of labeled oxycodone hydrochloride
sold by IMPAX after the Signing Date and such per milligram rate shall be increased by a
percentage equal to the amount of any announced percentage increase in

13

 

the
price of the wholesale acquisition cost of the Branded Product (as
defined in the Supplemental License Agreement) by
the Purdue Companies subsequent to the Signing Date under this Patent License Agreement (the
greater of such amounts, the “Aggregate Gross Margin”), determined in accordance with
United States generally accepted accounting principles, consistently applied (and derived from
IMPAX’s audited financial statements to the extent possible). In the event that the Purdue
Companies object to a determination made by IMPAX as to the Aggregate Gross Margin in connection
with a claim for indemnification made by the Purdue Companies hereunder, the Purdue Companies will
have the right to engage a CPA Firm to conduct an audit of IMPAX for the purposes of confirming the
Aggregate Gross Margin on substantially the same basis as in Section 2(c) hereof. The
determination made by the CPA firm following such audit of Aggregate Gross Margin shall be final
and binding on the Parties; provided, however, that IMPAX shall have the right, prior to such
determination becoming binding upon the Parties, to make a presentation to the CPA Firm (which
presentation shall be completed in one (1) business day) to ensure such CPA Firm has adequate
information to make its determination; provided further that, the Purdue Companies may be present
at such presentation and may make a presentation to the CPA firm following the IMPAX presentation.

          (b) The Purdue Companies shall defend, indemnify and hold harmless IMPAX, its Affiliates, and
the respective directors, officers, agents and employees of each of them (together, the “IMPAX
Parties”), from and against any and all Losses incurred by or rendered against the IMPAX Parties
resulting from (i) any claim, action or proceeding by any third party arising out of the sale by
the Purdue Companies of their controlled-release oxycodone product, including the product
OxyContin®, (ii) any claim, action or proceeding by any third party arising out of the
Purdue Companies material breach of any of their representations,

14

 

warranties, covenants or agreements made under this Patent License Agreement, and (iii) any
breach by the Purdue Companies of paragraph 5(c) of the Settlement Agreement or Section 1(e) of
this Patent License Agreement; provided, however, that the Purdue Companies will not be liable to
indemnify IMPAX for any Losses of IMPAX to the extent such Losses were caused by: (x) the
negligence or willful misconduct or wrongdoing of IMPAX or (y) any material breach by IMPAX of its
representations, warranties, covenants or agreements under this Patent License Agreement. The
provisions of this Section 7 shall not apply to any claims made by either Party or by third parties
under Federal or state antitrust or unfair competition laws.

     8. Purdue Companies Representations and Warranties: Covenant Not to Sue.

          (a) The Purdue Companies hereby represent and warrant as of the date hereof that: (i) each of
them has all necessary partnership or corporate, as applicable, power and authority to execute and
deliver this Patent License Agreement and to perform its obligations hereunder, and that the
execution, delivery and performance of this Patent License Agreement have been duly and validly
authorized by each of them; (ii) upon execution and delivery of this Patent License Agreement by
each of the Purdue Companies, this Patent License Agreement shall constitute the legal, valid and
binding agreement of each of them, enforceable against each of them in accordance with its terms,
subject to bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the
enforceability of creditors rights generally and other general equitable principles which may limit
the right to obtain certain remedies; (iii) neither the execution, delivery and performance of this
Patent License Agreement nor the consummation or performance of this Patent License Agreement by
the Purdue Companies shall contravene, conflict with or result in any material violation or
material breach, as the case may be, of any law applicable to the Purdue Patents or any material
contract to which the Purdue

15

 

Companies are a party; (iv) the Purdue Companies or their Affiliates collectively own all
right, title and interest in and to each and every patent and/or patent application within the
Purdue U.S. Patent Family, and have not granted or otherwise transferred to any third party any
right to enforce any patent or patent applications included in. the Purdue U.S. Patent Family, or
any right to practice any patent or patent applications included in the Purdue U.S. Patent Family
that would conflict with the License granted to IMPAX hereunder;
(v) the licenses granted to Teva Pharmaceuticals USA, Inc.
(“Teva”) and its Affiliates and Endo Pharmaceuticals
Holdings Inc. (“Endo”) and its Affiliates, respectively, are the only licenses or options to license to the
Purdue Patents granted by the Purdue Companies for the sale in the United States of any 10 mg, 20
mg, 40 mg or 80 mg controlled-release oxycodone product that is (A) an AB rated generic version of
OxyContin® as described in NDA No, 20-553, together with all amendments and supplements
thereto or (B) an authorized generic approved pursuant to NDA No. 20-553, together with all
amendments and supplements thereto, and (vi) to its knowledge, Purdue has not received any notice
of certification pursuant to 21 C.F.R § 3l4.94(a)(12)(i)(A)(4) for any. AB rated genetic version of
OxyContin® as described in NDA No. 20-553, together with all amendments and supplements
thereto from any third party other than Teva, Endo, Mallinckrodt
Inc., KV Pharmaceutical Company and Actavis Totowa LLC, or any of
their Affiliates. The Purdue Companies also represent and warrant
to IMPAX that any violation or breach of this Patent License Agreement by IMPAX may cause the
Purdue Companies to suffer substantial damages and irreparable harm, including causing the Purdue
Companies to be in violation or breach of, or severely disadvantaged under, certain material
agreements the Purdue Companies have entered into with third parties, provided however, that the
Purdue Companies acknowledge and agree

16

 

that IMPAX has not been provided a copy of such agreements nor an opportunity to review such
agreements.

          (b) 
The Purdue Companies hereby covenant that neither they, nor any of their Affiliates will sue,
assert any claim or counterclaim against or otherwise participate in any action or proceeding in
the United States against IMPAX or its Affiliates claiming that the manufacture, use, sale, offer
for sale or importation of IMPAX Product (i) pursuant to the License between the Signing Date and
the License Termination Date, and (ii) pursuant to the Supplemental License, assuming the
Supplemental License Agreement is entered into, between the Commencement Date and the Supplemental
License Termination Date, infringes any patents owned, licensed, or controlled by the Purdue
Companies or their Affiliates. Moreover, if and only if (1) the Supplemental License Agreement is
entered into and IMPAX does not breach Section 2(a) thereof, (2) the Purdue Companies or their
Affiliates assert one but not both claims of the U.S. Patent 5,508,042 in a case or proceeding
leading to the occurrence of the Terminal Date by virtue of paragraph 5(a)(B) of the Settlement
Agreement, and (3) IMPAX manufactures, uses, sells, offers for sale or imports 10, 20 or 40 mg
dosage strength IMPAX Product thereafter, then the Purdue Companies hereby covenant that neither
they nor any of their Affiliates will sue, assert any counterclaim against or otherwise participate
in any action or proceeding against IMPAX or its Affiliates in the United States claiming that the
manufacture, use, sale, offer for sale or importation of 10, 20 or 40 mg dosage strength IMPAX
Product infringes the claim of U.S. Patent No. 5,508,042 not asserted in the case or proceeding
leading to the occurrence of the Terminal Date by virtue of paragraph 5(a)(B) of the Settlement
Agreement; provided, however, if the judgment referred to in paragraph 5(a)(B) of the Settlement
Agreement is subsequently reversed or vacated or the case or proceeding is settled by the parties,
then such covenant shall terminate 48 hours after the issuance of such reversal or vacatur or 48
hours after IMPAX receives notice of the settlement of such case or proceeding. These covenants not
to sue shall be non-transferable, (except as provided in Section 12 of this Patent License
Agreement). Nothing in this Section shall be interpreted to prohibit the Purdue Companies from (A)
suing, asserting any claim or counterclaim against or otherwise participating in any action or
proceeding against IMPAX with respect to any formulations of oxycodone (other than the activities
permitted pursuant to the License or the Supplemental License or other than the covenants granted
in the first and second sentences of this Section 8(b)), or (B) enforcing this Patent License
Agreement,

17

 

the Settlement Agreement, the Supplemental License Agreement or the Consent Judgment.
Notwithstanding any provision herein to the contrary, this Section does not apply to, negate, or in
any way limit any legal rights which the Purdue Companies may have relating in any manner to claims
regarding any patents against owners, holders, licensees or beneficiaries of an ANDA (other than
the manufacture, use, sale, offer for sale or importation of IMPAX Product under clause (A) of the
immediately preceding sentence of this Section 8(b)) approved by, or submitted before or after the
date of this Patent License Agreement to, the FDA for a controlled-release oxycodone product that
is an AB rated generic version of OxyContin® (oxycodone hydrochloride controlled-release) Tablets
under NDA No. 20-553, together with all amendments and supplements thereto, regardless of whether
such ANDA owner, holder, licensee or beneficiary is or would otherwise be a manufacturer, supplier,
importer, distributor, purchaser or user of the IMPAX Product. The Purdue Companies further
acknowledge that: (I) the appropriate remedy for breach of this Section 8(b) by the Purdue
Companies is immediate dismissal, with prejudice of any patent infringement action brought in
breach of this Section 8(b); (II) time is of the essence in dismissing any action brought in breach
of this Section 8(b); and (III) that any available form of expedited relief to have the dismissal
granted and/or considered on appeal, including but not limited to, a motion for hearing on
shortened time, shall be appropriate in the event any of the Purdue Companies brings an action in
violation of this Section 8(b). The Purdue Companies further agree not to oppose directly or
indirectly, any motion to dismiss an action brought in breach of this Section 8(b) and not to
oppose any request for expedited ruling on such motion to dismiss.

          (c) The Purdue Companies hereby covenant that prior to the License Termination Date and
between the Commencement Date and the Supplemental License

18

 

Termination Date, if the Supplemental License Agreement is entered into, neither they, nor any
of their Affiliates, will file, assist (directly or indirectly) in the filing of, cause any other
person (directly or indirectly) to file, participate (directly or indirectly) in, or otherwise
assist (directly or indirectly) a citizens' petition under
21 CFR 10.30, 10.33 or 10.35 requesting agency action
inconsistent with the License or the Supplemental License; provided that IMPAX has been in full compliance with the
provisions of the fourth, fifth and sixth sentences of Section 2(a) of this Patent License
Agreement. The Purdue Companies further acknowledge that IMPAX would suffer substantial and
irreparable harm from their breach of this covenant, that IMPAX would not have an adequate remedy
at law for such breach, and that a temporary restraining order, preliminary injunction, and/or
permanent injunction requiring withdrawal of such citizens' petition would be an appropriate remedy for such breach.

     9. IMPAX’s Representations and Warranties. IMPAX hereby represents and warrants as of
the date hereof that: (i) it has all necessary corporate power and authority to execute and deliver
this Patent License Agreement and to perform its obligations hereunder, and that the execution,
delivery and performance of this Patent License Agreement have been duly and validly authorized by
it; (ii) upon execution and delivery of this Patent License Agreement by IMPAX, this Patent License
Agreement shall constitute the legal, valid and binding agreement of IMPAX, enforceable against it
in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium or
other similar laws affecting the enforceability of creditors’ rights generally and other general
equitable principles which may limit the right to obtain certain remedies; (iii) neither the
execution, delivery and performance by IMPAX of this Patent License Agreement nor the consummation
or performance of this Patent License Agreement by IMPAX shall contravene, conflict with or result
in any material violation or material breach, as the case may be, of any law applicable to IMPAX or
any material contract to

19

 

which IMPAX is a party; and (iv) no party other than IMPAX and DAVA is authorized to ship
items from IMPAX’s warehouse.

     10. Termination. In the event of a material breach by IMPAX of this Patent License
Agreement or the Settlement Agreement, the Purdue Companies will have the right to terminate this
Patent License Agreement upon written notice to IMPAX, such termination to take effect immediately
upon the delivery of such notice to IMPAX.

     11. DAVA Breach Event. Notwithstanding anything to the contrary contained in this
Patent License Agreement (except for liability in respect of Excess Sales in Section 2(b) hereof),
including without limitation the first sentence of Section 1(e) and the last sentence of Section
2(b) hereof, IMPAX shall not be deemed to have breached this Patent License Agreement to the extent
that such breach has resulted solely from the actions (or inactions) of DAVA under the DAVA Supply
Agreement that were not directly or indirectly taken (or not taken) at the direction of IMPAX or in
any way suggested, encouraged or expressly or tacitly approved of, authorized, waived or released
by IMPAX (any such event, a “DAVA Breach Event”), provided that IMPAX shall have complied with each
of the following:

               (i) Within two days of the Signing Date, IMPAX shall have delivered a written notice to DAVA
and DDN/Obergfel Pharmaceutical Logistics (“DDN”), in a form reasonably acceptable to the Purdue
Companies, notifying such persons of the License Termination Date, that such persons will be
prohibited from selling, offering for sale, making customer solicitations, or shipping IMPAX
Product from and after such date, that any rights granted to DAVA under Section 1(d) will have
expired, and, with respect to DAVA only, of IMPAX’s intention to pursue all available legal and
equitable remedies against DAVA to the

20

 

extent that DAVA takes any such actions from and after such date; including the sale, offer
for sale, distribution or shipment of IMPAX Product.

               (ii) Upon the earlier of (A) any time during the period commencing on June 7, 2007 and ending
on June 21, 2007 and (B) within two business days of receipt of a written request from the Purdue
Companies after the License Termination Date, IMPAX shall have delivered a written notice to DAVA
and DDN in the same form as the notice provided, under clause (i) above, notifying such persons of
the License Termination Date, that such persons will be prohibited from selling, offering, for
sale, making customer solicitations or shipping IMPAX Product from and after such date, that any
rights granted to DAVA under Section 1(d) will have expired, and, with respect to DAVA only, of
IMPAX’s intention to pursue all available legal and equitable remedies against DAVA to the extent
that DAVA takes any such actions from and after such date, including the sale, offer for sale,
distribution or shipment of IMPAX Product.

               (iii) IMPAX shall have used its best efforts to cause DAVA to deliver the certifications
required by Section 2(a) hereof.

               (iv) If the License Termination Date shall have occurred, IMPAX shall have delivered a written
notice to DAVA within two business days thereafter requesting that any IMPAX Product then in DAVA’s
possession or control promptly be returned to IMPAX, at IMPAX’s expense.

               (v) IMPAX shall forward copies of the notices referred to in clauses (i), (ii) and (iv) above
to the Purdue Companies in the manner provided in Section 16, within two business days of the
sending of each such notice,

21

 

               (vi) If a DAVA Breach Event shall have occurred, IMPAX shall pursue any and all legal and
equitable remedies it may have against DAVA in connection with the facts and circumstances giving
rise to such event, and shall allow the Purdue Companies to participate in any action or claim that
it makes and/or asserts against DAVA in relation thereto at IMPAX’s expense (including any expense
incurred by the Purdue Companies for the retention of its own counsel in connection with such
matter). Any recoveries made against DAVA in accordance with this Section 11 shall be for the
benefit of, and be promptly paid by IMPAX to, the Purdue Companies.

               (vii) IMPAX shall have monitored DAVA’s inventory levels of IMPAX Product prior to the License
Termination Data as reported to IMPAX under and in a manner consistent with the DAVA Supply
Agreement and via any other lawful method reasonably available to IMPAX, and shall have taken steps
reasonably calculated to ensure, based on such information, that IMPAX Product is not supplied to
DAVA in an amount that is reasonably anticipated to have resulted in Excess Sales, and to minimize
the inventory of IMPAX Product in DAVA’s possession or control as of the License Termination Date.

     12. No Assignment. This Patent License Agreement is binding upon and shall inure to
the benefit of each Party hereto and each of its successors and permitted assigns. IMPAX may not
assign (by way of merger, acquisition, statute, operation of law or otherwise) this Patent License
Agreement (an “Assignment”) without the prior written consent of the Purdue Companies which may be
withheld in the Purdue Companies’ sole discretion; provided, however, that the Purdue Companies’
consent shall not be required if such Assignment is part of
the transfer of all or substantially all of IMPAX’s assets or all of the equity or capital
stock of IMPAX; provided that such assignee is bound by and subject to the Settlement Agreement.
Any

22

 

Assignment, attempted Assignment or assignment of the rights granted hereunder by IMPAX, in
contravention of the provisions of this Section 12 shall be void and shall have no force or effect.
In the event that any of the Purdue Companies (or any of their respective successors and assigns)
sells or assigns (other than in connection with the grant of a security interest) any of the Purdue
Patents to any other person or entity, such person or entity shall agree to assume the obligations
of such Purdue Company under this Patent License Agreement in writing as a condition to such
acquisition.

     13. Entire Agreement. This Patent License Agreement, along with the Settlement
Agreement and the documents referred to herein and therein, set forth the entire agreement and
understanding among the Parties hereto as to the subject matter hereof and supersede all other
documents, oral consents or understandings, if any, made between the Purdue Companies and IMPAX
(excluding any agreements or stipulations endorsed by court order) before the Signing Date with
respect to the subject matter hereof. None of the terms of this Patent License Agreement shall be
amended or modified except in a writing signed by each of the Parties hereto. To the extent there
is an inconsistency between any provision of this Patent License Agreement and the Settlement
Agreement, the provisions of the Settlement Agreement shall govern. The Parties acknowledge that
there have been a number of drafts of this Patent License Agreement exchanged between them prior to
the Parties’ agreement on the final version of this Patent License Agreement which has been
executed by them. The Parties expressly agree that all such prior drafts have been superseded by
this executed Patent License Agreement and shall not be used in any dispute between the Parties as
evidence with respect to interpreting the meaning of any provision of this Patent License
Agreement.

23

 

     14. Enforceability. Any term or provision of this Patent License Agreement which is
invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the
extent of such invalidity or unenforceability, without rendering invalid or unenforceable the
remaining terms and provisions of this Patent License Agreement in such jurisdiction or in any
other jurisdiction.

     15. Governing Law. This Patent License Agreement, and the rights and obligations
created hereunder, shall be governed by and interpreted according to the substantive laws of the
State of New York without regard to its choice of law or conflicts of law principles.

     16. Notices. Any notice required under this Patent License Agreement shall be in
writing and shall be given (and shall be deemed to be duly given upon receipt) by delivery in
person, by facsimile or by registered or certified mail (postage prepaid, return receipt requested)
to the respective Parties at the following addresses (or at such other address for a Party as shall
be specified by like notice):

     If to any of the Purdue Companies:

Purdue Pharma L.P.

One Stamford Forum

201 Tresser Boulevard

Stamford, CT 06901-3431

Attn: Howard R. Udell

Executive Vice President

Chief Legal Officer

Fax No.: (203) 588-6204

with a copy to:

Chadbourne & Parke LLP

30 Rockefeller Plaza

New York, NY 10112

Attn: Stuart D. Baker

Fax No.: (212) 489-7130

If to IMPAX:

24

 

IMPAX Laboratories, Inc.

30831 Huntwood Avenue

Hayward, CA 94544

Attention: Chief Executive Officer

Fax No.: 510-471-1595

with a copy to:

IMPAX Laboratories, Inc.

30831 Huntwood Avenue

Hayward, CA 94544

Attention: Legal Department

Fax No.: 510-476-2092

     17. Effect of Waiver. A waiver by any Party of any term or condition of this Patent
License Agreement in any one instance shall not be deemed or construed to be a waiver of such term
or condition for any other instance in the future (whether similar or dissimilar) or of any
subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained
in this Patent License Agreement shall be cumulative and none of them shall be a limitation of any
other remedy, right, undertaking, obligation or agreement of any of the Parties.

     18. Legal Advice; Investigation. Each of the Parties agrees that it has received
independent legal advice from its attorneys with respect to the rights and asserted rights arising
out of this Patent License Agreement and the Settlement Agreement. Each of the Parties further
agrees that it and its counsel have had adequate opportunity to make whatever investigation or
inquiry they may deem necessary or desirable in connection with the subject matter of this Patent
License Agreement, prior to the execution hereof.

     19. Counterparts. This Patent License Agreement may be executed in counterparts
(including by facsimile or other electronic transmission), and each fully executed counterpart
shall be deemed an original of this Patent License Agreement.

     20. Definitions. All capitalized terms used herein and not defined shall have the
meanings specified in the Settlement Agreement. The definitions of the terms herein apply

25

 

equally to the singular and plural of the terms defined. Whenever the context may require,
any pronoun will include the corresponding masculine, feminine and neuter forms. The words
“include”, “includes” and “including” will be deemed to be followed by the phrase “without
limitation”. Unless the context requires otherwise, (A) any definition of or reference to any
agreement, instrument or other document herein will be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified
(subject to any restrictions on such amendments, supplements or modifications set forth herein or
therein) and (B) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be
construed to refer to this Patent License Agreement in its entirety and not to any particular
provision hereof.

[remainder of this page intentionally left blank]

26

 

Patent License Agreement Signature Page

     IN WITNESS WHEREOF, each of the Parties has caused this Patent License Agreement to be
executed as of the date first written above by its duly authorized officer or agent.

	 	 	 	 	 
	PURDUE PHARMA L.P.
  	 	 
	By:  	Purdue Pharma Inc., its general partner

 	 	 
	By:  	/s/ Edward B. Mahony
 	 	 
	 	Name:  	Edward B. Mahony 	 	 
	 	Title:  	Executive V.P., Chief Financial Officer 	 	 
	 
	THE P.F. LABORATORIES, INC.

 	 	 
	By:  	/s/ Edward B. Mahony
 	 	 
	 	Name:  	Edward B. Mahony 	 	 
	 	Title:  	Executive V.P., Chief Financial Officer 	 	 
	 
	PURDUE PHARMACEUTICALS L.P.

 	 	 
	By:  	Purdue Pharma Inc., its general partner

 	 	 
	By:  	/s/ Edward B. Mahony
 	 	 
	 	Name:  	Edward B. Mahony 	 	 
	 	Title:  	Executive V.P., Chief Financial Officer 	 	 
	 
	IMPAX LABORATORIES, INC.

 	 	 
	By:  	/s/ Larry Hsu
 	 	 
	 	Name:  	Larry Hsu 	 	 
	 	Title:  	President & CEO 	 	 
	 

     On April 12, 2007 before the undersigned Notary Public in and for Alameda County, California,
personally came and appeared Larry Hsu, who deposed and said that he initially affixed his
signature to this document on March 30, 2007 on behalf of Impax Laboratories, Inc. and appears
herein to execute the document in the presence of the undersigned Notary after being duly sworn.

	 	 	 	 	 
	 	 	 
	 	/s/ Larry Hsu
 	 
	 	Larry Hsu 	 
	 	 	 
	 	 	 
	 	/s/ Alison K. Skamangas
 	 
	 	Notary Public 	 
	 	 	 

 

 

	 	 	 	 	 

Schedule 1

To Patent License Agreement

	 	 	 	 	 
	Dosage Strength	 	Number of Bottles
	 
	 	 	 	 
	10 mg
	 	 	99,000	 
	20 mg
	 	 	173,000	 
	40 mg
	 	 	157,000	 
	80 mg
	 	 	94,000

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]